Figures & data
Figure 1. The cumulative (A) and daily (B) release of rifampicin (R) from composites of poly(L-lactide-co-ε-caprolactone) (PLCL) and β-tricalcium phosphate (TCP) with initial TCP contents of 0 wt%, 50 wt% and 60 wt% and rifampicin content of 8 wt%. Results shown as averages with standard deviations (n = 5).
![Figure 1. The cumulative (A) and daily (B) release of rifampicin (R) from composites of poly(L-lactide-co-ε-caprolactone) (PLCL) and β-tricalcium phosphate (TCP) with initial TCP contents of 0 wt%, 50 wt% and 60 wt% and rifampicin content of 8 wt%. Results shown as averages with standard deviations (n = 5).](/cms/asset/cb503aca-5b97-4ffe-80f8-20c82e2d6bb0/kbim_a_10922793_f0001.gif)
Figure 2. Bioluminescence results of the rifampicin containing (8 wt%) composites of poly(L-lactide-co-ε-caprolactone) and 50 wt% of β-tricalcium phosphate on a bacterial culture of light emitting Pseudomonas aeruginosa. Pellets containing rifampicin are on the lower row and corresponding composites without rifampicin are on the top row and act as controls.
![Figure 2. Bioluminescence results of the rifampicin containing (8 wt%) composites of poly(L-lactide-co-ε-caprolactone) and 50 wt% of β-tricalcium phosphate on a bacterial culture of light emitting Pseudomonas aeruginosa. Pellets containing rifampicin are on the lower row and corresponding composites without rifampicin are on the top row and act as controls.](/cms/asset/cb10afdd-2817-4f08-bf10-5a64035fa7cd/kbim_a_10922793_f0002.gif)
Figure 4. Weight average molar weight (Mw) (A), and mass loss and water absorption (B) of the studied composites as a function of time in vitro. The composites comprised of poly(L-lactide-co-ε-caprolactone) (PLCL) and β-tricalcium phosphate (TCP) and rifampicin (R) with initial TCP contents of 0 wt%, 50 wt% and 60 wt% and rifampicin content of 8 wt%. Error bars in part B are not visible due to the small values of standard deviations.
![Figure 4. Weight average molar weight (Mw) (A), and mass loss and water absorption (B) of the studied composites as a function of time in vitro. The composites comprised of poly(L-lactide-co-ε-caprolactone) (PLCL) and β-tricalcium phosphate (TCP) and rifampicin (R) with initial TCP contents of 0 wt%, 50 wt% and 60 wt% and rifampicin content of 8 wt%. Error bars in part B are not visible due to the small values of standard deviations.](/cms/asset/a279008b-e8de-4dfb-8e17-dd7da02d73d1/kbim_a_10922793_f0004.gif)
Figure 5. β-tricalcium phosphate (TCP) contents of the studied composites as a function of time in vitro. The composites comprised of poly(L-lactide-co-ε-caprolactone) (PLCL), TCP, and rifampicin (R) with initial TCP contents of 50 wt% (TCP50), and 60 wt% (TCP60) and rifampicin content of 8 wt%. Results shown as averages with standard deviations (n = 5).
![Figure 5. β-tricalcium phosphate (TCP) contents of the studied composites as a function of time in vitro. The composites comprised of poly(L-lactide-co-ε-caprolactone) (PLCL), TCP, and rifampicin (R) with initial TCP contents of 50 wt% (TCP50), and 60 wt% (TCP60) and rifampicin content of 8 wt%. Results shown as averages with standard deviations (n = 5).](/cms/asset/cb41cceb-eec7-4a11-a729-37a7e76b9519/kbim_a_10922793_f0005.gif)
Figure 6. Glass transition temperatures (Tg) (A) and melting enthalpies (ΔHf) (B) of the copolymer in the studied composites as a function of time in vitro. The composites comprised of poly(L-lactide-co-ε-caprolactone) (PLCL) and β-tricalcium phosphate (TCP) and rifampicin (R) with initial TCP contents of 0 wt%, 50 wt% and 60 wt%. Results shown as averages with standard deviations (n = 2–5).
![Figure 6. Glass transition temperatures (Tg) (A) and melting enthalpies (ΔHf) (B) of the copolymer in the studied composites as a function of time in vitro. The composites comprised of poly(L-lactide-co-ε-caprolactone) (PLCL) and β-tricalcium phosphate (TCP) and rifampicin (R) with initial TCP contents of 0 wt%, 50 wt% and 60 wt%. Results shown as averages with standard deviations (n = 2–5).](/cms/asset/8e190a64-ab75-4d4f-bee5-eb8895654ee6/kbim_a_10922793_f0006.gif)
Figure 7. SEM micrographs of the composites of poly(L-lactide-co-ε-caprolactone) (PLCL), 60 wt% of β-tricalcium phosphate (TCP) and rifampicin. (A–C) fractured surfaces after 0 weeks, 26 weeks and 52 weeks in vitro respectively. (D–F) outer surfaces after 0 weeks, 26 weeks and 52 weeks in vitro respectively.
![Figure 7. SEM micrographs of the composites of poly(L-lactide-co-ε-caprolactone) (PLCL), 60 wt% of β-tricalcium phosphate (TCP) and rifampicin. (A–C) fractured surfaces after 0 weeks, 26 weeks and 52 weeks in vitro respectively. (D–F) outer surfaces after 0 weeks, 26 weeks and 52 weeks in vitro respectively.](/cms/asset/5d77baf2-2ed2-4eba-9e38-0f32bc138fbb/kbim_a_10922793_f0007.gif)